|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01513 LIVZON PHARMA
Nominal 
37.280 -1.000 (-2.612%) | 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Turnover | 6,271,913 | -0.166% | 11,812,339 | 12,430,038 | 12,629,579 | 12,063,863 |
| Cost of Sales | -- | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- | -- |
| 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (25,222) | -50.295% | (204,203) | (348,754) | (197,582) | (87,342) | |
| Profit / (Loss) on Disposal | (150) | 95.870% | 45,203 | (170) | 861 | 7,035 | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 28,943 | 117.076% | 9,870 | 58,461 | 61,202 | 39,064 | |
| Profit / (Loss) before Taxation | 1,828,110 | 13.661% | 2,806,146 | 2,382,667 | 2,330,551 | 2,245,689 | |
| Taxation | (276,889) | 9.142% | (501,661) | (485,066) | (374,973) | (293,588) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (270,133) | 47.029% | (243,389) | 56,050 | (46,170) | (176,418) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 1,281,088 | 9.404% | 2,061,096 | 1,953,651 | 1,909,408 | 1,775,683 | |
| 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (165,118) | 112.802% | (155,890) | (271,502) | (268,761) | (70,041) |
| Depreciation & Amortisation | 313,375 | -7.779% | 627,240 | 887,900 | 685,630 | 471,339 |
| Directors' Emoluments | 6,503 | -0.245% | 18,942 | 18,324 | 18,702 | 19,795 |
| 2025/06 - Interim | %Chg (Compare to Interim) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2025/06 - Interim | %Chg (Compare to Interim) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| EPS (cts) | 143.000 | 12.598% | 224.000 | 210.000 | 204.000 | 190.000 |
| DPS (cts) | 0.000 | -- | 110.000 | 135.000 | 160.000 | 130.000 |
| Dividend Payout Ratio (%) | -- | -- | 49.107% | 64.286% | 78.431% | 68.421% |
| Cash flow per share ($) | -- | -- | 3.237 | 3.497 | 2.965 | 2.034 |
| NBV per share ($) | 15.129 | -- | 15.211 | 15.199 | 14.832 | 13.865 |
| Remarks: | Real time quote last updated: 22/08/2025 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 1,281,088 |
| %Change | 9.404% |
| EPS / (LPS) | RMB 1.430 |
| NBV Per Share (¥) | RMB 15.129 |